Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Debut is a vertically integrated synthetic biology company that combines AI-driven molecular discovery, skin genomics, and cell-free biomanufacturing to create high-performing, sustainable active ingredients and formulations for the beauty, cosmetics, and personal care industries. Utilizing its proprietary BeautyORB platform, the company screens billions of candidate molecules in silico against extensive skin-health genomic datasets to identify novel chemical entities that target the hallmarks of skin aging. Debut's advanced biomanufacturing capabilities, which combine precision fermentation and cell-free bioconversions, allow it to produce bio-identical and novel ingredients with superior purity and potency compared to traditional sourcing. In addition to supplying ingredients and custom formulations to major global partners like L'Oréal and Natura, Debut operates its own direct-to-consumer skincare brand, DEINDE, which focuses on addressing inflammaging and promoting skin longevity.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Debut.